Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy

Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy

Meng-Chao Luo,1,2,* Jia-Yi Wu,1,3,* Jun-Yi Wu,1,3 Zhong-Tai Lin,1,2 Yi-Nan Li,3 Zhen-Xin Zeng,3 Shao-Ming Wei,1,2 Mao-Lin Yan1,3 1Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian Province, 350001, People’s Republic of China; 2Department of General Surgery...

Full description

Bibliographic Details
Main Authors: Luo MC, Wu JY, Lin ZT, Li YN, Zeng ZX, Wei SM, Yan ML
Format: Article
Language:English
Published: Dove Medical Press 2023-10-01
Series:Journal of Hepatocellular Carcinoma
Subjects:
unresectable hepatocellular carcinoma
alpha-fetoprotein
des-gamma-carboxyprothrombin
combination therapy
tumor response
Online Access:https://www.dovepress.com/early-tumor-marker-response-predicts-treatment-outcomes-in-patients-wi-peer-reviewed-fulltext-article-JHC

Internet

https://www.dovepress.com/early-tumor-marker-response-predicts-treatment-outcomes-in-patients-wi-peer-reviewed-fulltext-article-JHC

Similar Items